Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antithymocyte globulin - Sanofi

Next Previous
X
Search
Drug Profile

Antithymocyte globulin - Sanofi

Alternative Names: anti-thymocyte globulin; anti-thymocyte globulin (rabbit); Antithymocyte immunoglobulin; ATG; Polyclonal rabbit antithymocyte globulin; Rabbit antithymocyte globulin; Rabbit-ATG; rATG; Thymoglobulin; Thymoglobuline

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi pasteur
  • Developer Cedars-Sinai Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; University of Texas M. D. Anderson Cancer Center; Virginia Commonwealth University
  • Class Polyclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aplastic anaemia; Bone marrow transplant rejection; Graft-versus-host disease; Liver transplant rejection; Pancreas transplant rejection; Renal transplant rejection; Transplant rejection
  • Phase II Heart transplant rejection; Myelodysplastic syndromes; Type 1 diabetes mellitus

Most Recent Events

  • 19 Oct 2020 Phase II development is still ongoing Heart transplant rejection (Prevention) in USA (IV) (NCT03292861)
  • 16 Jul 2019 Sanofi Company completes a phase I/II trial in Type-1 diabetes mellitus (Combination therapy) in USA (IV) (NCT01106157)
  • 23 Oct 2018 No development reported - Phase-II for Liver transplant rejection (Combination therapy, Prevention) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top